-

Compass Pathways to Participate in Two Investor Conferences in December

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the following December investor conferences:

  • 8th Annual Evercore Healthcare Conference – Coral Gables, FL: Fireside chat at 10:00am ET on December 2, 2025
  • Piper Sandler 37th Annual Healthcare Conference – New York, NY: Fireside chat at 1:30pm ET on December 3, 2025

A live audio webcast of these events will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.

About Compass Pathways

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational COMP360 synthetic psilocybin treatment, potentially a first in class treatment. COMP360 has Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD).

Compass is headquartered in London, UK, with offices in New York in the US. We envision a world where mental health means not just the absence of illness but the ability to thrive.

Contacts

Enquiries

Media: Dana Sultan-Rothman, media@compasspathways.com, +1 484 432 0041
Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7324

Compass Pathfinder Limited

NASDAQ:CMPS

Release Versions
$Cashtags

Contacts

Enquiries

Media: Dana Sultan-Rothman, media@compasspathways.com, +1 484 432 0041
Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7324

Social Media Profiles
More News From Compass Pathfinder Limited

Compass Pathways to Highlight Scientific Research and TRD Disease State Education Efforts at the 2026 Neuroscience Education Institute Fall Congress

LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced its participation at the 2026 Neuroscience Education Institute (NEI) Fall Congress, taking place in Colorado Springs, CO, from November 5-8. The Company will feature its Change the Tune in TRD educational campaign for U.S. HCPs focused on TRD, as well as encore presentations from its COMP360...

Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026

LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that it will release financial results for the third quarter ended September 30, 2026, and provide an update on recent developments, on November 3, 2026. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on November 3, 2026. A live webcast of the call will be available...

Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day

LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the first-ever TRD Awareness Day in the U.S., a day dedicated to recognizing and advocating for individuals, caregivers and communities impacted by TRD. The campaign is being amplified by leading mental health organizations, including National Alliance on Mental Illness (NAMI), Mental Health...
Back to Newsroom